Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran

Mehrdad Payandeh¹, Masoud Sadeghi^2, , Edris Sadeghi³ and Anita Kabir koohian⁴

¹Department of Hematology and Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Department of Nursing, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴Department of Biology, Faculty of Basic Sciences, Science and Research Breanch, Islamic Azad University, Tehran, Iran

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi and Anita Kabir koohian. Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran. American Journal of Cancer Prevention. 2014; 2(2):37-41. doi: 10.12691/ajcp-2-2-4

Abstract

To evaluate the concordance and discordance between IHC and FISH results for detection of Her2/neu protein, analyses of ER and PR, and also evaluation of the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) –positive invasive ductal carcinoma enrolled onto the Herceptin adjuvant. IHC analysis of ER, PR and HER2 was performed in 133 patients of breast cancer with invasive ductal carcinoma. 90(67.6%) cases were confirmed by FISH. Statistical analysis was performed with IBM SPSS version 19, Kaplan-Meier method and log-rank test. Age mean of patients was 46.39±10.81 years (range, 24-78 years). Concordance rates between IHC and FISH were 32.4% for IHC 2+ and 81.25% for IHC 3+ (P<0.001). There were 17 and 56 patients of IHC 2+ and 3+ with ER positive and also 23 and 59 patients of IHC 2+ and 3+ had PR positive.The 83 patients had age ≤50 years and 50 patients had >50 years. Of 133 the patients, 48(36.1%) patients were treated with trastuzumab and 85(63.9%) were treated without trastuzumab. The overall survival(OS) for patients treating with trastuzumab were mean of 37.8 months and the OS for patients treating without trastuzumab were mean of 20.8 months (P<0.05). The results are that trastuzumab therapy is effective and improves the survival of HER2-positive breast cancer patients and trastuzumab therapy is effective and tolerated for breast cancer with Her-2 positive. There is a statistically significant relationship between ER positive with PR positive and ER negative with PR negative that these results need to more studies with more patients in the world.

Keywords:
ER FISH PR survival trastuzumab

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	M Y, Ahmadi M R H, J K, H P, K H A, M R Y, et al. An 8 years retrospective study of breast cancer incidence in ilam province, Western iran. J Clin Diagn Res.2013. 7(12): 2923-5.
[2]	Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, et al. The breast cancer working group presentation divided into three sections: the epidemiology, pathology and treatment of breast cancer. Jpn J Clin Oncol. 2010.40(Suppl 1):i13-18.
[3]	Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014. 2014: 513158.
[4]	Cui H, Cheng Y, Piao SZ, Xu YJ, Sun HH, Cui X, et al. Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. Cancer Cell Int. 2014 Jan 29.14(1): 10.
[5]	Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb. 2(2): 127-37.
[6]	Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013. 33(3): 411-7.
[7]	Rexer BN, Chanthaphaychith S, Dahlman KB, Arteaga CL. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res. 2014. 16(1): R9.
[8]	Khabaz MN. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia? Asian Pac J Cancer Prev. 2014.15(19): 8395-400.
[9]	Keyhani E, Muhammadnejad A, Behjati F, Sirati F, Khodadadi F, Karimlou M, et al. Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents. Asian Pac J Cancer Prev. 2013.14(12): 7651-6.
[10]	Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol. 2014.10(14): 2293-301.
[11]	Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer. 2014. [Epub ahead of print]
[12]	Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, et al. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer. 2013. 13: 351.
[13]	Jiang H, Bai X, Meng F, Zhang C, Zhang X. Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance. Oncol Lett. 2014. 7(6): 1954-1958.
[14]	Sui W, Ou M, Chen J, Wan Y, Peng H, Qi M, et al. Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J Surg Oncol. 2009. 7: 83.
[15]	Qiao EQ, Ji M, Wu J, Li J, Xu X, Ma R, et al. Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer. Mol Clin Oncol. 2013.1(4):703-710.
[16]	Ha JH, Seong MK, Kim EK, Lee JK, Seol H, Lee JY, et al. Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients. J Breast Cancer. 2014. 17(1): 33-9.
[17]	Varga Z, Noske A, Ramach C, Padberg B, Moch H. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer. 2013.13:615.
[18]	Ghaffari SR, Sabokbar T, Dastan J, Rafati M, Moossavi S. Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). Asian Pac J Cancer Prev. 2011. 12(4): 1031-4.
[19]	Shirsat HS, Epari S, Shet T, Bagal R, Hawaldar R, Desai SB. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization. Indian J Pathol Microbiol. 2012. 55(2): 175-9.
[20]	Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer. 2012.118(4):914-23.
[21]	DE Vargas Wolfgramm E, Gavioli CF, Entringer ML, Alves LN, Stur E, DE Castro Neto AK, et al. Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil. Mol Clin Oncol. 2013.1(2):353-358.
[22]	Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz VS, Visscher D, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013.15(6): R104.
[23]	Sofi GN, Sofi JN, Nadeem R, Shiekh RY, Khan FA, Sofi AA, et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev. 2012.13(10): 5047-52.
[24]	Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, et al. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS One. 2013.8(8): e72175.
[25]	Shomaf M, Masad J, Najjar S, Faydi D. Distribution of breast cancer subtypes among Jordanian women and correlation with histopathological grade: molecular subclassification study. JRSM Short Rep. 2013.4(10):2042533313490516.
[26]	Okita Y, Narita Y, Suzuki T, Arita H, Yonemori K, Kinoshita T, et al. Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol. 2013.1(6):995-1001.
[27]	Gultekin M, Eren G, Babacan T, Yildiz F, Altundag K, Guler N, et al. Metaplastic breast carcinoma: a heterogeneous disease. Asian Pac J Cancer Prev. 2014.15(6): 2851-6.